Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate X4 Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding X4 Pharmaceuticals, Inc.’s stock price such as:

• X4 Pharmaceuticals, Inc.’s current stock price and volume
• Why X4 Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for XFOR from analysts
• XFOR’s stock price momentum as measured by its relative strength

About X4 Pharmaceuticals, Inc. (XFOR)

Before we jump into X4 Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.

Want to learn more about X4 Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about X4 Pharmaceuticals, Inc..

What Caused X4 Pharmaceuticals, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of June 30, 2026,, no analysts have changed their rating of X4 Pharmaceuticals, Inc.’s stock over the last month.

Additionally, you'll want to evaluate X4 Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on X4 Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

X4 Pharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about X4 Pharmaceuticals, Inc. (XFOR) by visiting AAII Stock Evaluator.

Relative Price Strength of X4 Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 30, 2026, X4 Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of 17.38%, which translates to a Momentum Score of 88 and is considered to be Very Strong.

Want to learn more about how X4 Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

X4 Pharmaceuticals, Inc. Stock Price: Bottom Line

As of July 1, 2026, X4 Pharmaceuticals, Inc.’s stock price is $4.215, which is down 9.74% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like X4 Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.